Regeneron and Sanofi Start Human Trials of Arthritis Drug as Possible COVID-19 Treatment
Regeneron (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have started a clinical trial to see if Kevzara -- a drug that has been approved by the Food and Drug Administration as an arthritis treatment -- works on COVID-19. The companies hope that the monoclonal antibody will reduce fever and the need for supplemental oxygen in patients with severe cases of the illness.
Because they are working with a drug that has already been approved, the companies can skip the phase 1 trial stage, in which a drug's safety profile is established. Kevzara already has a proven safety record in patients. The only question is whether it helps against COVID-19.
Image source: Getty Images
Source Fool.com
